Pain can negatively affect a person’s quality of life and impede recovery from illness or injury. Recent research compiled by the American Massage Therapy Association (AMTA) suggests that massage can be a helpful pain management strategy for manually controlling symptoms in people suffering metastatic cancer and rheumatoid arthritis, among other illnesses, as well as post-cardiac surgery pain.
To view Multimedia News Release, go to http://www.multivu.com/mnr/61665-amta-massage-therapy-for-pain-relief-cancer-arthritis-post-cardiac-surgery
Nearly 90 percent of children and adults with a highly aggressive form of acute lymphoblastic leukemia (ALL) showed no evidence of cancer after receiving a novel, personalized cell therapy that reprograms a patient’s immune system. In pilot studies of bioengineered T cells that attack leukemia, 24 of 27 patients (89%) experienced complete responses within 28 days after treatment. In all, 27 patients received the treatment--22 children treated at The Children’s Hospital of Philadelphia and five adults treated at the Hospital of the University of Pennsylvania.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/64394-chop-penn-harness-engineered-t-cells-eliminate-tumors-in-blood-leukemia
To mark National Massage Therapy Awareness Week (NMTAW), October 20-26, the American Massage Therapy Association (AMTA) has compiled research that suggests symptoms of stress, anxiety and depression (all associated with mental health) may be alleviated with massage therapy.
To view Multimedia News Release, go to http://www.multivu.com/mnr/63936-amta-massage-therapy-research-roundup-mental-health-benefits
Philips Respironics, a unit of Royal Philips (NYSE: PHG, AEX: PHI) and a pioneer in science-based sleep solutions, today announces a significant advancement in sleep therapy with the commercial release of a first of its kind minimal contact nasal mask – Wisp. Designed to fit more than 98% of sleep apnea patients, Wisp brings distinctive styling and patented technology for a better overall mask experience that may improve patient compliance.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/62230-philips-respironics-announces-advancement-in-sleep-therapy-with-wisp
Three and a half years after beginning a clinical trial which demonstrated the first successful and sustained use of genetically engineered T cells to fight leukemia, a research team from the Perelman School of Medicine at the University of Pennsylvania and the Children’s Hospital of Philadelphia will today announce the latest results of studies involving both adults and children with advanced blood cancers that have failed to respond to standard therapies. The findings from the first 59 patients who received this investigational, personalized cellular therapy, known as CTL019, will be presented during the American Society of Hematology’s Annual Meeting and Exposition in New Orleans.
To view Multimedia News Release, go to http://www.multivu.com/mnr/64691-penn-medicine-reports-research-leukemia-patients-cellular-therapy-ctl019
By reprogramming a 7–year–old girl’s own immune cells to attack an aggressive form of childhood leukemia, a pediatric oncologist has achieved a complete response in his patient, who faced grim prospects when she relapsed after conventional treatment. The innovative experimental therapy used bioengineered T cells, custom–designed to multiply rapidly in the patient, and then destroy leukemia cells. After the treatment, the child’s doctors found that she had no evidence of cancer.
To view Multimedia News Release, go to http://www.multivu.com/mnr/50777-chop-engineered-immune-t-cell-therapy-anticancer-effect-in-children
Lung cancer is the most common cause of cancer-related death worldwide, with the highly malignant small cell lung cancer having the worst prognosis. In recent years the surge of immunotherapy has given cancer sufferers new hope.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/64826-issels-recurrent-lung-cancer-responds-to-integrative-immunotherapy
Philips Respironics, a unit of Royal Philips (NYSE: PHG, AEX: PHIA) and a pioneer in science-based sleep solutions, brings a new comfort option to its best-selling, most comfortable full face mask that fits most patients. The Amara gel cushion option is part of a groundbreaking series of new masks and services that are setting a new standard for patient care.
To view Multimedia News Release, go to http://www.multivu.com/mnr/64501-philips-respironics-amara-gel-cushion-face-mask-sleep-apnea
Until recently, cancer patients looking for the most precise form of proton radiation therapy – “pencil-beam scanning” – had to narrow their search to about a half dozen centers in the United States that offer this treatment on a limited basis.
Today’s opening of the Scripps Proton Therapy Center in San Diego, Calif., marks the first time that a proton center in the United States is treating patients exclusively with this ultra-accurate technology, in every treatment room.
To view Multimedia News Release, go to http://www.multivu.com/mnr/65691-scripps-proton-therapy-center-san-diego-precise-cancer-care
Check out Lori Copeland\'s journey about teaching massage therapy at centennial college. Get more information about massage therapy program at http://www.centennialcollege.ca/Programs/ProgramOverview.aspx?Program=5110
Steve Scott became one of the greatest mile runners in American history by taking a strategic approach to his craft. Now 58, Scott is seeking a competitive advantage of a different sort since recently being diagnosed with prostate cancer. Scott publicly revealed his current cancer battle today at the Cougar Challenge, a cross country meet at California State University San Marcos, where he is head coach of the track and field and cross country programs.
To view the Multimedia News Release, go to: http://www.multivu.com/players/English/7350051-scripps-health-steve-scott-reveals-proton-treatments-for-prostate-cancer
Today, the Pharmaceutical Research and Manufacturers of America (PhRMA) released a new report, “A Decade of Innovation in Rare Diseases,” to document the significant progress made in the last 10 years in understanding a broad range of rare diseases and translating this knowledge into groundbreaking therapies for a variety of patient populations.
The report illustrates that more than 230 new medicines to treat rare or “orphan” diseases were approved by the U.S. Food and Drug Administration (FDA) in the last decade, and there are currently more than 450 orphan drugs in development.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7350554-phrma-report-innovation-rare-diseases/
